Lung-MAP S1400 Lung Master Protocol Update Meeting. Friday, September 16, :15 to 3:45 pm

Similar documents
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.

PATHOLOGY WEBINAR. SESSION 2: March 20th, David Gandara, MD S1400 Study Co-Chair/UC Davis Comprehensive Cancer Center.

Where We ve Been & Where We re Going SWOG FALL MEETING OCTOBER 5, 2018

IROC Imaging and Radiation Oncology Quality Assurance for the NCTN

Agenda. David Gandara, MD. Vassiliki Papadimitrakopoulou, MD. Lawrence Schwartz, MD Michael Knopp, MD, PhD. Informed Consent, Quality Assurance

The Clinical Research E-News

MULTI-GROUP AUDITS, THE CENTRAL MONITORING PORTAL, AND OTHER CTSU UPDATES

Fall 2018 Research Training Program Agenda. S E S SI ON 1, Tuesday, S eptember 11, 2018

S1400 LUNG MASTER PROTOCOL

NCI/Local Protocol #: RTOG-0521/RTOG NCI Protocol Version Date: December 22, 2014 (Broadcast date: 2/2/2015)

SWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology

The Clinical Research E-News

Sheila Prindiville, MD, MPH Director Coordinating Center for Clinical Trials National Cancer Institute

TMIST: Frequently Asked Questions

Nationwide Children s Hospital Biospecimen Core Resource Training

The Clinical Research E-News

ROLE OF PRMS FROM START TO FINISH. Tricia Adrales Bentz, MHA Hollings Cancer Center

The Clinical Research E-News

Clinical Trial Design to Expedite Drug Development Mary W. Redman, Ph.D.

October 12 13, 2018 New York Marriott Marquis New York, New York. The premier conference for annual updates in lung cancer. 23rd Annual Conference

EMERGING THERAPIES FOR BLOOD CANCERS:

Oncology Clinical Trials Conference

Where We Are: NCI s Informed Consent Template and Updates to Address Changing Needs

3.1.4 The phrase, and only focal nuclear, was clarified to and/or only focal nuclear.

RAVE DATA ENTRY GUIDELINES S1400 & SUB-STUDIES. Protocol Ver. 1/8/18

Clinical Trial Credentialing:

Validation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D

The National Cancer Institute Community Oncology Research Program (NCORP) A Local Story

Logistics of Alchemist Screening Trial A Alliance Fall Group Meeting CRP Breakout Session November 5, 2015

Design considerations for Phase II trials incorporating biomarkers

Guideline for the Diagnosis of Breast Cancer

NCI/Local Protocol #: RTOG-1005/RTOG NCI Protocol Version Date: July 31, 2014

Importance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine

For Protocol Amendment 5 of: RTOG 0938, A Randomized Phase II Trial of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer

International RT Clinical Trial Group Membership & Quality Control BY DR YING XIAO

NSABP B-55/BIG Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department. NRG Oncology - Pittsburgh, Pennsylvania

2015 Cancer Program Public Report

NCI Protocol Version Date: October 11, 2016 (Broadcast: November 7, 2016) The protocol version date was updated

Instructions for Completing the UVMCC Clinical Research Protocol Submission Form UVMCC CLINICAL RESEARCH PROTOCOL SUBMISSION FORM

The National Accreditation Program for Breast Centers American Program Considerations

Current Topics in Breast Cancer Symposium

This section was clarified to direct questions regarding eligibility to the study data manager.

The Clinical Research E-News

FAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated

Mary Ann Hodorowicz RDN, MBA, CDE, CEC (Certified

The Clinical Research E-News

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.

NSABP: FB-11. Shannon Puhalla, MD

TRAUMA RECOVERY/HAP OPERATING GUIDELINES

UW Medicine Neuropathology

Complete breast care from the team that cares. Breast Center

An effective interdisciplinary team structure for initiatives based on this QI model would contain the following representatives:

Demystifying the Cell Biology of Cancer

10 th Annual Oncology Spring Forum

The Clinical Research E-News

IBCSOMS Certificate of Added Qualification Handbook

The Clinical Research E-News

Standards Deficiency Resolution

Clinical Research Unit Charter

Prostate Cancer Clinical Trials - PHEN s Rally Update and Next Steps

The Business of Spine The Business of Spine

THE BREAST CENTER AT MONTEFIORE NYACK HOSPITAL

LCA Lung Clinical Forum. 21 st October 2014

ESSENTIALS IN SPINE: MIS APPROACHES TO LUMBAR & CERVICAL SPINE A BioSkills Experience

Preanalytic Variables in Cytology: Lessons Learned from Next Generation Sequencing

Jefferson Kimmel Cancer Center Network Presents: The Clinical Research E-News. January 14, 2009

Response to. GPhC Consultation. Guidance to ensure a safe and effective pharmacy team.

Worta McCaskill-Stevens, M.D., M.S. Director, NCORP Chief, Community Oncology and Prevention Trials Research Group Division of Cancer Prevention

Cancer Committee Report to the Community

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar

FAQs for UK Pathology Departments

National Capital Chapter

The Business of Spine

See Important Reminder at the end of this policy for important regulatory and legal information.

Successful Immunization Program For Health Care Workers and Residents in Long Term Care. By Vicky S Lyman, RN, BSN, ICP, WCC

CoreAlign Teacher Training Paragon Pilates & Physical Therapy 2019

Tuesday, May 15th & Saturday, May 19th

Hospice & Palliative Care

Parisa Mirzadehgan, MPH, CCRP

Greetings & Welcome. Rosa Berardi Program Officer Coleman Palliative Medicine Lead

Page 1, column 2, entry for Lech Papiez: Line 2: Former was added in front of Medical Lines 4-7 of his entry were deleted.

Logistics of Alchemist Screening Trial A Shauna Hillman, Statistician Chelsea Schultz, Data Manager Alliance SDC

College of American Pathologists

Trial record 1 of 1 for:

The Clinical Research E-News

Innovations in Breast Ultrasound

Corporate Medical Policy

OSTEOPOROSIS ESSENTIALS: DENSITOMETRY, DIAGNOSIS & MANAGEMENT

Advances in Oncology th Annual. October 10-11, 2014 Hyatt Regency Sacramento, CA CONFERENCE DIRECTORS

In 2014, the National Cancer Institute will launch a series of

2016 Fall Conference Exhibit/Sponsor Prospectus

Navigating Alliance Protocols

SKCN E-Newsletter Volume 9 ISSUE 9 Regional Network Office

Alliance Organizational Structure. Trini Ajazi, MM Alliance Chief Administrative Officer Clinical Research Professional Orientation

Clinical Trial Review Guide

Table of Contents. Why Become a Fitness Instructor for the City of Saskatoon?... 3

Wednesday, June 22, 2016

Guideline for the Handling of Pathology Lung Tissue Specimens

Transcription:

Lung-MAP S1400 Lung Master Protocol Update Meeting Friday, September 16, 2016 2:15 to 3:45 pm Hyatt Regency Chicago Regency D (West Tower, Gold Level) Agenda Welcome Study Updates Study Logistics / S1400I Patient Reported Outcomes Karen Kelly, MD SWOG Lung Committee Chair Vassiliki (Vali) Papadimitrakopoulou, MD Study Chair, Medical Oncology Mary Redman, PhD Lead Biostatistician Quality Assurance and Monitoring Accrual Enhancement Committee Elaine Armstrong, MS SWOG Quality Assurance Manager Roy Herbst, MD, PhD, Medical Oncology Site Coordinators Committee Jessica Jordan, BA Site Coordinator Committee Chair Questions and Answers David Gandara, MD, Moderator

S1400 Registration and Study Flow Screen for eligibility, consent patient and confirm that required amount of tissue is available for submission (pathologist must complete the S1400 Local Pathology Review Form) Register to S1400 in OPEN* Submit tissue specimen to Foundation Medicine, Inc. within 1 day after registration and log shipment in SWOG Specimen Tracking System If pre-screening prior to progression When patient progresses, submit Notice of Progression* Within 1 day after form submission (provided at least 16 days have passed since tissue submission) If screening at progression Within 16 days after tissue submission Site staff receives email with sub-study assignment* (Assignment will also display in the Sub-study Assignment Form in Rave ) Evaluate/confirm sub-study common eligibility and sub-study specific eligibility criteria If patient meets sub-study common eligibility criteria but does NOT meet sub-study specific eligibility criteria If patient IS eligible for and consents to assigned sub-study Register to S1400X sub-study in OPEN after receiving sub-study assignment email If patient is NOT eligible for any sub-study Submit Notice of Intention not to Register Form in Rave Submit Request for Sub-study Reassignment Form in Rave Submit S1400 Request for New Sub-study Assignment Form in Rave Administer protocol treatment within 7 working days of sub-study registration, conduct follow-up, obtain and submit specimens, radiology images and forms per sub-study protocol Patient progresses on S1400X sub-study and is potentially eligible for another sub-study Follow and submit required forms until 3 years from registration or death (whichever comes first) per S1400 screening protocol September 1, 2016 *If it is determined that a patient will not register to a sub-study at any time following S1400 registration, the Notice of Intention Not to Register form must be submitted. Should the decision to not register a patient to their assigned sub-study be reversed, sub-study registration is allowed despite submission of the Notice of Intention Not to Register form.

LUNG-MAP S1400 Site Coordinator Committee The Lung-MAP Site Coordinator Committee (SCC) was formed in July 2016. The members are site staff from a variety of institutions, NCTN affiliations, and geographical locations who work closely with the study leadership. The members provide recommendations and feedback on accrual strategies, patient and promotional materials, changes to study procedures, data collection, and staff training materials. Look for their face or name on their badge and let them know your concerns, questions, or helpful advice for making Lung-MAP collaborative and successful. You can also contact them at LungmapSCC@crab.org. Joan Aresco joan.aresco@stjoeshealth.org 734-712-3304 ECOG-ACRIN Jamie Arnett, BSN, RN, OCN arnettj@somc.org 740-356-7594 Alliance Wanda M. Burdette RN, OCN, CCRP wburdette@gibbscc.org 864-560-6810 Co-Chair Lavinia Dobrea RN, MS, OCN Lavinia.Dobrea@stjoe.org 714-734-6214 Chair Jessica Jordan, BA jessica.jordan@va.gov 203-932-5711 ext 3287 Steffany Lim, CCRP sllim@ucdavis.edu 916-734-0561 SWOG NRG Veteran s Affairs Connecticut / SWOG SWOG Kathy Malatesta, RN, OCN, CCRC kathy.malatesta@mainegeneral.org 207-626-4855 Alliance Joan Moore, MSN, RN, OCN, CCRP jmoore@wellspan.org 717-339-2638 NRG Nichole Rykbos 901-326-8359 Nichole.Rykbos@BMHCC.org Minority/SWOG Stephanie Smith, RN, MSN, OCN smiths1@sjchs.org 912-819-5723 ECOG-ACRIN Tyler Workman, RN, MSN tworkman@queens.org 808-691-8583 Minority/SWOG

LUNG-MAP TISSUE SPECIFICATIONS FOR LUNG-MAP S1400 Study requirement TUMOR CONTENT 20% including tumor volume 0.2 mm 3 It is important that the specimen contains as much tumor content as possible to ensure that there s enough DNA needed for sequencing. S1400 requires adequate tissue for biomarker profiling. For details, please refer to the S1400 protocol Section 5 for eligibility requirements and Section 15 for a complete description of tissue requirements. Specimens must be submitted using the SWOG Specimen Tracking System, a process outlined in the S1400 protocol Section 15. NOTE FOR LIVER SPECIMENS: It is recommended that at least 40% of the specimen contain malignant cells to ensure sufficient tumor DNA. For Best Results, Use These Specifications SPECIMEN TYPE FFPE BLOCK or 12-20 SLIDES (+H&E SLIDE) Tissue must be formalin-fixed and paraffin embedded. A tissue block is preferred. If sending slides: -- A minimum of 12 unstained, charged, and unbaked 4-5 micron slides are required. --20 slides are highly recommended. -- Slides should include an additional H&E or Aperio stained slide (If unavailable, submit an extra unstained slide). For core biopsy tissue, use 3-5 cores embedded in a single block, aligned so that when cut, the blade is running parallel to the long axis of the cores. Fine needle aspirates with good cellularity are acceptable as long as cell blocks are established. Biopsy tissue can be from primary or metastatic sites. Bone biopsies are not allowed. NUCLEATED CELLULARITY 80 % Specimens containing less than 80% nucleated cells require greater total volume and may not be suitable to assay. A total of 75,000 to 150,000 nucleated cells are recommended. 5mm SURFACE AREA 25 mm 2 The face of the block or slide should be at least 25 mm 2 in area (for example, 5x 5 mm or 2.5 x 10mm). OR 25mm 2 5mm 5mm BLOCK 25mm 2 OR 5mm SLIDES SPECIMEN VOLUME 1 mm 3 (including tumor volume 0.2 mm 3 ) The total volume (surface area x depth) of the block or stacked slides should be at least 1 mm 3. If the surface area is 25 mm 2 as recommended, the depth should be at least 40 microns. For this reason, a minimum of 12 slides is required. In addition, the specimen must contain a tumor volume 0.2 mm 3. OR 40 microns ] ] 40 microns PRIOR TO ENROLLMENT, YOUR LOCAL PATHOLOGIST MUST SIGN OFF ON THE S1400 LOCAL PATHOLOGY REVIEW FORM CERTIFYING THAT TISSUE REQUIREMENTS HAVE BEEN MET. Questions? Email: S1400question@crab.org

FUNDING HIGHLIGHTS Sites will receive up to $5,869 ($1,079 screening/ $4,790 registration) for each patient on trial o Additional Site Payment for patients registered to S1400 of $500 for a limited duration. If biopsies are needed, sites will receive $3,000/$6,000 for the biopsies performed at screening and/or progression after initial response on Arm1 Sites will be reimbursed for additional research based procedures Sites will be reimbursed $1,333 for on-site visits outside the regular audit schedule Funding Questions: SWOG Group Chair s Office, funding@swog.org For additional information, see funding memos Version 8/14/2016

WHO DO I ASK? CONTACT LIST Eligibility / Data Submission Protocol / Regulatory Public Relations / Media Louise Highleyman and Kara Amber Data Coordinators SWOG Data Operations Center (206) 652-2267 S1400Question@crab.org Specimen Fred R. Hirsch, MD, PhD (303) 724-3858 fred.hirsch@ucdenver.edu Crystal Miwa Protocol Coordinator SWOG Operations Office (210) 614-8808 ext 1019 cmiwa@swog.org Philip C. Mack, PhD (916) 734-8022 pcmack@ucdavis.edu Wendy Lawton SWOG Communications Manager SWOG Group Chair s Office (503) 348-8675 lawtonw@ohsu.edu Imaging Lawrence H. Schwartz, MD (212) 305-8994 lhs2120@cumc.columbia.edu Specimen and Imaging Submission Foundation Medicine Inc. (617) 418-2200 S1400@foundationmedicine.com TRIAD SWOG1400@irocohio.org or call IROC Ohio at 614-293-2929 USA Investigational Drug Distribution Pharmaceutical Management Branch (PMB) Matthew Boron (240) 276-6575 PMBAfterHours@mail.nih.gov Funding Federal funding: Pat Mize, MBA Accounting Specialist (503) 418-4533 mizep@ohsu.edu Non-federal funding: Casey Dawson Financial Administration: SWOG-CTI (503) 494-5517 dawsoca@ohsu.edu Distribution Email: funding@swog.org Lung-Map S1400 Update Meeting Page 1 of 2 SWOG Fall 2016 Group Meeting Version 4.0 08.31.2016

WHO DO I ASK? CONTACT LIST S1400 Treatment-related/Medical Vassiliki Papadimitrakopoulou, MD Study Chair (713) 792-6363 S1400MedicalQuery@swog.org Sub-Study Treatmentrelated/ Medical S1400A S1400AMedicalQuery@swog.org Roy S. Herbst, MD (203) 785-6879 S1400MedicalQuery@swog.org Study Chair Vassiliki A. Papadimitrakopoulou, MD (713) 792-6363 David R. Gandara, MD (916) 734-3771 S1400MedicalQuery@swog.org Hossein Borghaei, DO NCTN Group: ECOG-ACRIN (215) 214-4297 S1400B S1400BMedicalQuery@swog.org S1400C S1400CMedicalQuery@swog.org S1400D S1400DMedicalQuery@swog.org S1400E S1400EMedicalQuery@swog.org S1400I S1400IMedicalQuery@swog.org S1400G S1400GMedicalQuery@swog.org Corey J. Langer, MD NCTN Group: NRG (215) 615-5121 Martin J. Edelman, MD NCTN Group: ALLIANCE (410) 328-8708 Charu Aggarwal, MD, MPH NCTN Group: ECOG-ACRIN (215) 662-6318 Mark A. Socinski, MD NCTN Group: ALLIANCE (412) 692-4724 Scott N. Gettinger, M.D. NCTN Group, SWOG (203) 785-7564 Taofeek K. Owonikoko, M.D., Ph.D. MSCR NCTN Group, ECOG-ACRIN (404) 778-5575 James L. Wade III, M.D. (217) 876-6600 Kathy S. Albain, MD (708) 327-3102 Primo N. Lara, Jr., MD (916) 734-5959 Lyudmila A. Bazhenova, M.D. NCTN Group: Alliance (858) 822-6189 Lauren A. Byers, M.D. (713) 792-6363 Lung-Map S1400 Update Meeting Page 2 of 2 SWOG Fall 2016 Group Meeting Version 4.0 08.31.2016